Literature DB >> 3234637

Polymerisation and crosslinking of fibrin monomers in diabetes mellitus.

A Lütjens1, T W Jonkhoff-Slok, C Sandkuijl, E A vd Veen, J vd Meer.   

Abstract

Polymerisation and crosslinking of fibrin monomers was studied in 35 healthy volunteers and in 42 poorly controlled diabetic patients. Polymerisation did not show any difference between control subjects (n = 10) and diabetic patients (n = 11) (p greater than 0.1), although fibrinogen was 35% more glycated in the diabetic patients (p less than 0.001). Alpha chain crosslinking in the diabetic patients, however, was impaired as is shown from an increase in intermediate alpha polymers with a concomitant decrease in alpha monomer disappearance. A significant positive correlation was found between the degree of glycation of fibrinogen and the defective alpha chain polymerisation (r = 0.86, p less than 0.005). These results were consistent with the results of thrombin and reptilase experiments. The reaction rate with reptilase did not show any difference between the two groups (p greater than 0.1), whereas the reaction rate with thrombin was significantly slower in the diabetic group compared to the control subjects (p less than 0.001). Purified fibrin clots obtained from the diabetic patients were more susceptible to plasmin than clots obtained from control subjects. It is concluded that in poorly controlled diabetic patients polymerisation of fibrin monomers is normal, but crosslinking of the alpha chains is impaired, leading to a higher susceptibility of the clots to plasmin degradation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3234637     DOI: 10.1007/bf00277485

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  [A SCREENING-TEST, FOLLOWED BY A RAPID QUANTITATIVE MICRODETERMINATION OF PLASMA FIBRINOGEN].

Authors:  T STRENGERS; E G ASBERG
Journal:  Ned Tijdschr Geneeskd       Date:  1963-11-02

2.  Fibrinogen-fibrin interaction.

Authors:  V A Belitser; T V Varetskaja; G V Malneva
Journal:  Biochim Biophys Acta       Date:  1968-02-19

3.  Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Diabetes       Date:  1983-07       Impact factor: 9.461

4.  Evidence for four different polymerization sites involved in human fibrin formation.

Authors:  S A Olexa; A Z Budzynski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

5.  Non-enzymatic glucosylation of fibrinogen.

Authors:  B A McVerry; S Thorpe; F Joe; P Gaffney; E R Huehns
Journal:  Haemostasis       Date:  1981

6.  Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.

Authors:  B Lipinski; I Lipinska; A Nowak; V Gurewich
Journal:  J Lab Clin Med       Date:  1977-07

7.  Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.

Authors:  R L Jones; C M Peterson
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

8.  Glycosylation of human fibrinogen in vivo.

Authors:  A Lütjens; A A te Velde; E A vd Veen; J vd Meer
Journal:  Diabetologia       Date:  1985-02       Impact factor: 10.122

9.  The role of fibrin deposition in diabetic glomerulosclerosis: a light, electron and immunofluorescence microscopy study.

Authors:  A Farquhar; M K MacDonald; J T Ireland
Journal:  J Clin Pathol       Date:  1972-08       Impact factor: 3.411

10.  Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy.

Authors:  J Kłoczko; M Wojtukiewicz; M Bielawiec; B Zarzycka; I Kinalska
Journal:  Acta Haematol       Date:  1986       Impact factor: 2.195

View more
  5 in total

1.  Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model.

Authors:  Marlien Pieters; Namukolo Covic; Francois H van der Westhuizen; Chandrasekaran Nagaswami; Yelena Baras; Du Toit Loots; Johann C Jerling; Dale Elgar; Kathryn S Edmondson; Danie G van Zyl; Paul Rheeder; John W Weisel
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

2.  Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes.

Authors:  Seong-Joon Lee; Ji Man Hong; Sung Eun Lee; Dae Ryong Kang; Bruce Ovbiagele; Andrew M Demchuk; Jin Soo Lee
Journal:  BMC Neurol       Date:  2017-05-19       Impact factor: 2.474

3.  Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.

Authors:  Judith J de Vries; Charlotte J M Snoek; Dingeman C Rijken; Moniek P M de Maat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-09       Impact factor: 8.311

4.  Fibrin Fiber Stiffness Is Strongly Affected by Fiber Diameter, but Not by Fibrinogen Glycation.

Authors:  Wei Li; Justin Sigley; Marlien Pieters; Christine Carlisle Helms; Chandrasekaran Nagaswami; John W Weisel; Martin Guthold
Journal:  Biophys J       Date:  2016-03-29       Impact factor: 4.033

5.  Fibrinogen Glycation and Presence of Glucose Impair Fibrin Polymerization-An In Vitro Study of Isolated Fibrinogen and Plasma from Patients with Diabetes Mellitus.

Authors:  Boguslawa Luzak; Magdalena Boncler; Marcin Kosmalski; Ewelina Mnich; Lidia Stanczyk; Tomasz Przygodzki; Cezary Watala
Journal:  Biomolecules       Date:  2020-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.